[Form 4] Regulus Therapeutics Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 Overview: The filing documents that Regulus Therapeutics Inc. (RGLS) Chief Executive Officer and Director Joseph P. Hagan disposed of 100 % of his equity holdings—both common shares and derivative securities—on 25 June 2025. The disposition was automatic and stems from the previously-announced $7.00-per-share cash tender offer and merger between Regulus and Novartis AG, executed through wholly-owned subsidiary Redwood Merger Sub Inc.

Cash & CVR consideration: • Every Regulus common share became entitled to $7.00 in cash plus one contingent value right (CVR). • Each performance stock unit (280,750 PSUs) was converted to the same economics.
• All in-the-money stock options (exercise price below $7.00) were cancelled in exchange for a cash payment equal to intrinsic value plus one CVR per underlying share.
• All out-of-the-money options (exercise ≥ $7.00 but < $14.00) were cancelled for CVRs only, giving potential future cash of up to $14.00 less exercise price upon milestone achievement.
• Outstanding warrants were settled for $2.95 per warrant, the Black-Scholes value defined in the merger agreement.

Securities affected: 571,558 common shares, 5,388,976 option shares (multiple strike prices from $1.00 to $13.10), and 2,976 warrant shares were all reduced to zero beneficial ownership. Following the closing, Hagan holds no direct or indirect equity in Regulus, which is now a wholly owned Novartis subsidiary.

Investor takeaway: The filing is procedural but confirms the legal closing of the Novartis-Regulus merger and the extinguishment of public equity. Shareholders can expect prompt cash settlement and potential upside from the CVR tied to a specified milestone.

Positive

• Merger consummation provides definitive $7.00 cash exit for shareholders, removing deal-completion uncertainty and crystallising value.
• Contingent Value Right offers additional upside of up to $7.00 per share if the specified milestone is met, retaining growth optionality without further capital at risk.

Negative

• All outstanding stock options and PSUs cancelled; insiders, including the CEO, now have no ongoing equity incentive in the legacy entity.
• Future value hinges entirely on milestone success; failure to achieve the milestone renders CVRs and converted options/warrants worthless.

Insights

M&A Specialist

TL;DR – Filing confirms Regulus–Novartis deal closed; all equity converted to $7 cash plus CVR, eliminating public float.

The Form 4 is a mechanical insider filing but carries material confirmation of transaction completion. It details the exact treatment of every equity instrument under the April 29 2025 Merger Agreement. Cash-plus-CVR consideration crystallises value for common holders and in-the-money options, while out-of-the-money options convert solely into CVRs, preserving optional upside without additional cash cost to Novartis. Settlement of warrants at their Black-Scholes value removes residual dilution. With Hagan’s beneficial ownership dropping to zero, governance shifts entirely to Novartis, signalling full integration. For arbitrageurs, the document eliminates closing-risk concerns; focus now turns to the milestone that would trigger the additional $7.00 CVR payment.

Portfolio Manager

TL;DR – Liquidity event finalised; cash received, future CVR optionality remains the only upside lever.

From a portfolio perspective, the filing locks in a 100 % exit at $7.00—a premium already reflected when the tender was announced. Remaining exposure is binary: the CVR pays $7.00 upon milestone achievement, otherwise zero. Investors should mark the equity position as realised and monitor CVR probability. No residual equity float means the RGLS ticker will delist, shifting valuation tracking solely to the unlisted CVR instrument.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hagan Joseph P

(Last) (First) (Middle)

C/O REGULUS THERAPEUTICS INC.

4224 CAMPUS POINT CT., #210

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Regulus Therapeutics Inc. [ RGLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/25/2025		D(1)(2)		571,558	D	(3)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$9.5	06/25/2025		D(1)(2)			6,500	(5)	(5)	Common Stock	6,500	(5)	0	D
Stock Option	$9.5	06/25/2025		D(1)(2)			1,000	(5)	(5)	Common Stock	1,000	(5)	0	D
Stock Option	$6.4	06/25/2025		D(1)(2)			100,000	(4)	(4)	Common Stock	100,000	(4)	0	D
Stock Option	$13.1	06/25/2025		D(1)(2)			90,000	(5)	(5)	Common Stock	90,000	(5)	0	D
Stock Option	$2.6	06/25/2025		D(1)(2)			160,000	(4)	(4)	Common Stock	160,000	(4)	0	D
Stock Option	$13.1	06/25/2025		D(1)(2)			30,000	(5)	(5)	Common Stock	30,000	(5)	0	D
Stock Option	$1.48	06/25/2025		D(1)(2)			100,000	(4)	(4)	Common Stock	100,000	(4)	0	D
Stock Option	$1.36	06/25/2025		D(1)(2)			1,312,500	(4)	(4)	Common Stock	1,312,500	(4)	0	D
Stock Option	$1.3	06/25/2025		D(1)(2)			249,000	(4)	(4)	Common Stock	249,000	(4)	0	D
Stock Option	$2.01	06/25/2025		D(1)(2)			990,000	(4)	(4)	Common Stock	990,000	(4)	0	D
Stock Option	$1	06/25/2025		D(1)(2)			1,350,000	(4)	(4)	Common Stock	1,350,000	(4)	0	D
Common Stock Purchase Warrant (Right to Buy)	$7.46	06/25/2025		D(1)(2)			2,976	(6)	(6)	Common Stock	2,976	(6)	0	D

Explanation of Responses:

1. This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share.

2. Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.

3. Pursuant to the terms of the Merger Agreement, (i) each Share was converted into the right to receive the Offer Price and (ii) each performance stock unit ("PSU") was canceled and converted into the right to receive (A) an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of Shares underlying such PSU immediately prior to the Effective Time by (y) the Closing Amount plus (B) one CVR with respect to each such Share subject to such PSU immediately prior to the Effective Time. The 280,750 PSUs reported herein were unintentionally omitted from previous Form 4 filings made by the Reporting Person following the achievement of the performance-based vesting conditions applicable thereto.

4. Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an "In-the-Money Option") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time.

5. Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an "Out-of-the-Money Option") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option).

6. Pursuant to the Merger Agreement, the Reporting Person elected to receive $2.95 per warrant, an amount equal to the Black Scholes Value (as defined in the Merger Agreement) for the warrants reported herein.

	/s/ Christopher Aker, Attorney-in-Fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Regulus Therapeutics (RGLS) shareholders receive at closing?

Each share converted into $7.00 in cash plus one contingent value right (CVR) for potential future payment.

Why were Joseph Hagan’s stock options cancelled?

Under the Merger Agreement, options were automatically cancelled and paid out in cash or CVRs depending on strike price relative to the $7.00 offer.

How were Regulus warrants treated in the merger?

Warrants were settled for $2.95 in cash per warrant, equal to their Black-Scholes value, eliminating further dilution.

Does Joseph Hagan still hold any Regulus equity after the transaction?

No. The Form 4 shows zero common shares, options, or warrants remaining after 25 June 2025.

What triggers the additional $7.00 CVR payment?

The CVR pays upon achieving the milestone defined in the CVR Agreement; details are not specified in the Form 4.